2023 World Conference on Lung Cancer (Posters)-EP13.07. Treatment Patterns and Outcomes in Recent US Clinical Practice for SCLC Patients After Two Prior Lines of Therapy

EP13.07. Treatment Patterns and Outcomes in Recent US Clinical Practice for SCLC Patients After Two Prior Lines of Therapy - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the treatment patterns and outcomes in a large cohort of small cell lung cancer (SCLC) patients who had received two prior lines of therapy. The researchers analyzed data from a nationwide database of electronic health records and included patients who had progressed following a front-line platinum-based regimen with or without a programmed cell death ligand 1 (PD-L1) inhibitor.<br /><br />The study included 326 SCLC patients in the third-line (3L) cohort. The majority of patients were white and had extensive stage disease at diagnosis. The most common sites of metastasis were the brain or CNS, bone, and liver. About 29% of patients in the 3L cohort had received front-line therapy with a platinum-based regimen combined with a PD-L1 inhibitor.<br /><br />The researchers found that the median duration of 3L therapy was 51 days, with a median overall survival (rwOS) of 5.3 months and a median progression-free survival (rwPFS) of 2.5 months. Similar results were observed in patients who received front-line platinum-based regimen with anti-PD-L1 therapy.<br /><br />Overall, the study concluded that outcomes for SCLC patients in later lines of therapy remain poor, even in recent times. The researchers emphasized the need for new therapeutic options to address this high unmet need in the SCLC population.<br /><br />The findings from this study provide important insights into treatment patterns and outcomes for SCLC patients who have received two prior lines of therapy. This information may inform the development of new therapeutic strategies to improve patient outcomes in this challenging disease.

Asset Subtitle

Hossein Borghaei

Meta Tag

Speaker Hossein Borghaei

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

small cell lung cancer

treatment patterns

outcomes

cohort

electronic health records

progression

platinum-based regimen

PD-L1 inhibitor

metastasis

therapeutic options